BioCardia (BCDA) 10-K 9 Apr 20 2019 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 20, 2020	Jun. 30, 2019
Document Information [Line Items]
Entity Registrant Name	BioCardia, Inc.
Entity Central Index Key	0000925741
Trading Symbol	bcda
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		6,848,355
Entity Public Float			$ 23,226,531
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $0.001

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 5,585	$ 5,358
Accounts receivable, net of allowance for doubtful accounts of $2 and $9 at December 31, 2019 and December 31, 2018	147	274
Inventory	4	141
Prepaid expenses and other current assets	642	445
Total current assets	6,378	6,218
Property and equipment, net	181	145
Operating lease right-of-use asset, net	1,065
Other assets	54	54
Total assets	7,678	6,417
Current liabilities:
Accounts payable	914	743
Accrued expenses and other current liabilities	2,561	1,805
Operating lease liability - current	528
Total current liabilities	4,003	2,548
Operating lease liability - noncurrent	614
Deferred revenue	691
Deferred rent		77
Total liabilities	5,308	2,625
Stockholders’ equity:
Preferred stock, $0.001 par value, 25,000,000 shares authorized as of December 31, 2019 and December 31, 2018; no shares issued and outstanding as of December 31, 2019 and December 31, 2018
Common stock, $0.001 par value, 100,000,000 shares authorized as of December 31, 2019 and December 31, 2018; 6,825,183 and 4,845,697 shares issued and outstanding as of December 31, 2019 and December 31, 2018	7	5
Additional paid-in capital	103,433	90,148
Accumulated deficit	(101,070)	(86,361)
Total stockholders’ equity	2,370	3,792
Total liabilities and stockholders’ equity	$ 7,678	$ 6,417

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Allowance for doubtful accounts	$ 2,000	$ 9,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	6,825,183	4,845,697
Common stock, shares outstanding (in shares)	6,825,183	4,845,697

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue:
Total revenue	$ 710	$ 625	$ 479
Costs and expenses:
Cost of goods sold	358	517	690
Research and development	8,562	8,453	5,799
Selling, general and administrative	6,003	5,757	6,395
Total costs and expenses	14,923	14,727	12,884
Operating loss	(14,213)	(14,102)	(12,405)
Other income (expense):
Interest income	87	118	95
Gain on change in fair value of redemption feature embedded in convertible notes	52
Interest expense	(112)
Loss on extinguishment of convertible notes	(521)
Other expense	(2)	(3)	2
Total other income (expense)	(496)	115	97
Net loss	$ (14,709)	$ (13,987)	$ (12,308)
Net loss per share, basic and diluted (in dollars per share)	$ (2.61)	$ (3.28)	$ (2.90)
Weighted-average shares used in computing net loss per share, basic and diluted (in shares)	5,644,328	4,264,178	4,240,060
Product [Member]
Revenue:
Total revenue	$ 182	$ 282	$ 389
Collaboration Agreement [Member]
Revenue:
Total revenue	$ 528	$ 343	$ 90

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Restricted Stock Units (RSUs) [Member]Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016		4,236,813
Balance at Dec. 31, 2016		$ 4	$ 80,720	$ (60,142)	$ 20,582
Exercise of stock options (in shares)		9,706
Exercise of stock options			144		144
Share-based compensation			2,707		2,707
Net loss				(12,308)	(12,308)
Issuance of restricted stock units in lieu of 2018 cash bonus
Balance (in shares) at Dec. 31, 2017		4,246,519
Balance at Dec. 31, 2017		$ 4	83,571	(72,450)	11,125
Exercise of stock options (in shares)		237
Exercise of stock options			4		4
Share-based compensation			2,774		2,774
Net loss				(13,987)	(13,987)
Adjustments to opening balance for change in accounting principle at Dec. 31, 2017				76	76
Issuance of stock and warrants, net of issuance costs (in shares)		592,597
Issuance of stock and warrants, net of issuance costs		$ 1	3,799		3,800
Restricted stock units vested and issued (in shares)	6,344
Issuance of restricted stock units in lieu of 2018 cash bonus
Balance (in shares) at Dec. 31, 2018		4,845,697
Balance at Dec. 31, 2018		$ 5	90,148	(86,361)	$ 3,792
Exercise of stock options (in shares)
Share-based compensation			2,722		$ 2,722
Net loss				(14,709)	(14,709)
Issuance of stock and warrants, net of issuance costs (in shares)		1,741,667
Issuance of stock and warrants, net of issuance costs		$ 2	9,194		9,196
Restricted stock units vested and issued (in shares)		27,426
Reverse stock split fractional share true up (in shares)		(494)
Issuance of stock and warrants from conversion of convertible notes (in shares)		210,887
Issuance of stock and warrants from conversion of convertible notes			1,204		1,204
Issuance of restricted stock units in lieu of 2018 cash bonus			165		165
Balance (in shares) at Dec. 31, 2019		6,825,183
Balance at Dec. 31, 2019		$ 7	$ 103,433	$ (101,070)	$ 2,370

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Issuance costs	$ 1,259	$ 200

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating activities:
Net loss	$ (14,709,000)	$ (13,987,000)	$ (12,308,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Write-off of inventory	1,000
Depreciation	111,000	88,000	78,000
Reduction in the carrying amount of right-of-use assets	440,000
Gain on change in fair value of redemption feature embedded in convertible notes	(52,000)
Loss on extinguishment of convertible notes	521,000
Non-cash interest expense on convertible shareholder notes	112,000
Share-based compensation	2,722,000	2,774,000	2,707,000
Changes in operating assets and liabilities:
Accounts receivable	127,000	(179,000)	(21,000)
Inventory	136,000	49,000	(56,000)
Prepaid expenses and other current assets	(198,000)	(104,000)	16,000
Accounts payable	171,000	119,000	377,000
Accrued liabilities excluding accrued interest on convertible note	922,000	240,000	415,000
Operating lease liability - current	88,000
Deferred revenue	691,000	(65,000)	96,000
Operating lease liability - noncurrent	(528,000)
Deferred rent		(4,000)	25,000
Net cash used in operating activities	(9,445,000)	(11,069,000)	(8,671,000)
Investing activities:
Purchase of property and equipment	(146,000)	(66,000)	(136,000)
Purchase of short-term investments			(1,800,000)
Maturity of short-term investments			1,800,000
Net cash used in investing activities	(146,000)	(66,000)	(136,000)
Financing activities:
Proceeds from sale of common stock and warrants	10,452,000	4,000,000
Issuance costs from sales of common stock and warrants	(1,259,000)	(200,000)
Proceeds from convertible loan payable	625,000
Proceeds from the exercise of common stock options		4,000	144,000
Net cash provided by financing activities	9,818,000	3,804,000	144,000
Net change in cash and cash equivalents	227,000	(7,331,000)	(8,663,000)
Cash and cash equivalents at beginning of period	5,358,000	12,689,000	21,352,000
Cash and cash equivalents at end of period	5,585,000	5,358,000	12,689,000
Supplemental disclosure for noncash investing and financing activities:
Conversion of notes and interest payable to stock and warrants	633,000
Issuance of restricted stock units in lieu of 2018 cash bonus	165,000
Right-of-use asset obtained in exchange for lease obligation	$ 1,505,000

Note 1 - Summary of Business

Note 1 - Summary of Business	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	( 1 Summary of Business (a) Description of Business BioCardia, Inc., or the Company, is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. Its lead therapeutic candidate is the CardiAMP cell therapy system and its second The Company has three 1 2 3

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	( 2 Significant Accounting Policies (a) Basis of Presentation and Consolidation These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All material intercompany accounts and transactions have been eliminated during the consolidation process. Certain changes in the prior period consolidated balance sheet have been made to conform to the current period presentation. Specifically, accounts payable was decreased by $277,000 December 31, 2018 December 31, 2018, 2017, 2016 $39,000 2019 no (b) Liquidity - Going Concern The Company has incurred net losses and negative cash flows from operations since its inception and had an accumulated deficit of $101.1 December 31, 2019. $5.6 December 31, 2019 not second 2020. one not The Company’s ability to continue as a going concern and to continue further development of its therapeutic candidates beyond the second 2020, not not may may (c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires Company management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property and equipment, right-of-use assets and related liabilities, allowances for doubtful accounts and sales returns; inventory valuation, derivative instruments, clinical accruals, and share-based compensation. (d) Cash Equivalents The Company classifies all highly liquid investments with an original maturity date of 90 (e) Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At December 31, 2019, one not not (f) Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and do not not $2,000 $9,000 December 31, 2019 2018, (g) Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the average-cost method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company analyzes its inventory levels quarterly and writes down inventory that has become obsolete or has a cost basis in excess of its expected net realizable value or inventory quantities in excess of expected requirements. Excess requirements are determined based on comparison of existing inventories to forecasted sales, with consideration given to inventory shelf life. Expired inventory is disposed of and the related costs are recognized in cost of goods sold. (h) Property and Equipment, Net Property and equipment, net, are carried at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets, as described in the table below. Maintenance and repairs are expensed as incurred. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is reflected in the accompanying consolidated statements of operations. Asset Estimated useful lives (in years) Computer equipment and software 3 Laboratory and manufacturing equipment 3 Furniture and fixtures 3 Leasehold improvements 5 years or lease term, if shorter (i) Right-of-Use Assets Operating lease right-of-use asset and liabilities 12 The Company’s lease liabilities are recognized at the applicable lease commencement date based on the present value of the lease payments required to be paid over the lease term. Variable lease payments are expensed as incurred and are not The Company's ROU assets are also recognized at the applicable lease commencement date. The ROU asset equals the carrying amount of the related lease liability, adjusted for any lease payments made prior to lease commencement and lease incentives provided by the lessor, if any. The Company reduces a right-of-use (ROU) asset, and the periodic reduction is the difference between the straight-line total lease cost for the period (including reduction of initial direct costs) and the periodic accretion of the lease liability using the effective interest method. The Company’s lease terms may The Company’s lease contracts often include lease and non-lease components. The Company has elected the practical expedient offered by the standard to not The Company has elected not twelve (j) Long-lived Assets Impairment assessment of long - lived assets may not December 31, 2019, no ( k ) Clinical Trial Accruals As part of the process of preparing its consolidated financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiation and may not not may may ( l ) Derivatives The Company accounts for its derivative instruments as either assets or liabilities on the consolidated balance sheet and measures them at fair value. Derivatives are adjusted to fair value through other (expense) income, net in the consolidated statements of operations. ( m ) Deferred Rent Prior to the adoption of ASU No. 2018 11, 842 ( n ) Revenue Recognition Net product revenue Collaboration agreement revenue In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may not The Company applies judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, if over time, concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in the Company’s estimated measure of progress are accounted for prospectively as a change in accounting estimate. The Company recognizes collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. The Company will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company’s balance sheets. If the related performance obligation is expected to be satisfied within the next twelve may not one December 31, 2019, $691,000 $191,000 $500,000 July 2021. Multiple contracts with the same customer - two one one Contract costs - one not Contract modifications - one not not not ( o ) Shipping Costs Costs incurred for the shipping of products to customers totaled approximately $6,000, $6,000 $5,000 December 31, 2019, 2018 2017, ( p ) Product Warranties The Company provides a standard warranty of serviceability on all its products for the duration of the product’s shelf life, which is two not December 31, 2019 2018. ( q ) Research and Development The Company’s research and development costs are expensed as incurred. Research and development expense include the costs of basic research activities as well as other research, engineering, and technical effort required to develop new products or services or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and support costs for collaborative partnering programs wherein the Company provides biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. The Company’s research and development costs consist primarily of: • Salaries, benefits and other personnel-related expenses, including share-based compensation • Fees paid for services provided by clinical research organizations, research institutions, consultants and other outside service providers • Costs to acquire and manufacture materials used in research and development activities and clinical trials • Laboratory consumables and supplies • Facility-related expenses allocated to research and development activities • Fees to collaborators to license technology • Depreciation expense for equipment used for research and development and clinical purposes. (r ) Cost of Goods Sold (s ) Share-Based Compensation The Company measures and recognizes share-based compensation expense for equity awards to employees, directors and consultants based on fair value at the grant date. The Company uses the Black-Scholes option pricing model to calculate fair value of its stock option grants. The compensation cost for restricted stock awards is based on the closing price of the Company’s common stock on the date of grant. Share-based compensation expense recognized in the consolidated statements of operations is based on the period the services are performed and recognized as compensation expense on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur. Measurement of nonemployee awards - The measurement of equity-classified nonemployee awards is fixed at the grant date, and the Company may 505 50 The Black-Scholes option pricing model (BSM) requires the input of subjective assumptions, including the risk-free interest rate, the expected volatility in the value of the Company’s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, the share-based compensation expense could be materially different in the future. These assumptions are estimated as follows: Risk-free Interest Rate The risk-free interest rate assumption is based on the zero Expected Volatility The Company has limited historical data of its own to utilize in determining expected volatility. As such the Company based the volatility assumption on a combined weighted average of the Company’s own historical data and that of a selected peer group. The peer group was developed based on companies in the biotechnology and medical device industries whose shares are publicly-traded. Expected Term The expected term represents the period of time that options are expected to be outstanding. As the Company does not (t ) Income Taxes The Company accounts for income taxes based on the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets, liabilities, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not not In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, forecasts of future taxable income, and ongoing tax planning. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not The Company recognizes and measures benefits for uncertain tax positions using a two first not not second 50% No (u ) Fair Value of Financial Instruments The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the consolidated financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Where observable prices or inputs are not The Company’s financial assets and liabilities consist principally of cash and cash equivalents, accounts receivable, and accounts payable. The fair value of the Company’s cash equivalents is determined based on quoted prices in active markets for identical assets. The recorded values of the Company’s accounts receivable and accounts payable approximate their current fair values due to the relatively short-term nature of these accounts. (v ) Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Common stock equivalents are comprised of restricted stock units, warrants to purchase common stock and options outstanding under the stock option plans. For all periods presented, there is no (w ) Recently Adopted Accounting Pronouncements In February 2016, No. 2016 02, Leases (Topic 842 2016 02” July 2018, No. 2018 11, 842 No. 2018 11. No. 2018 11, 2016 02, The Company adopted the new standard using the cumulative-effect method on January 1, 2019. March 2019. The FASB made available several practical expedients in adopting the amended lease accounting guidance. The Company elected the package of practical expedients permitted under the transition guidance, which among other things, allowed registrants to carry forward historical lease classification, its assessment on whether a contract is or contains a lease, and its initial direct costs for any leases that exist prior to adoption of the new standard. BioCardia also elected to keep leases with an initial term of 12 The most significant impact was the recognition of ROU assets and related lease liabilities for operating leases on the condensed consolidated balance sheet. The Company recognized ROU assets and related lease liabilities of $1,505,000 $1,593,000 January 1, 2019. not 6 In June 2018, No. 2018 07, 718 2018 07 2018 07 718, No 2018 07 505 50, 2018 07 January 1, 2019 not not In May 2014, No. 2014 09, 605, 606, 2015 2016, 606 January 1, 2018 In May 2017, No. 2017 09 718 2017 09 718. 2016 01 January 1, 2018, not ( x ) Recent Accounting Pronouncements In August 2018, No. 2018 13, 820 2018 13 820. 3 2018 13 December 15, 2019, not In November 2018, No. 2018 18, 808 808 606 2018 18” 2018 18 606 606 2018 18 December 15, 2019, 2018 18 606. not In December 2019, 2019 12 740 December 15, 2020, In June 2016, No. 2016 13, 326 December 15, 2022, not Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did not not

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	( 3 ) Fair Value Measurements The fair value of financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company follows a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into the following three Level 1 Level 2 not Level 3 no The following table sets forth the fair value of the financial assets measured on a recurring basis as of December 31, 2019 2018 As of December 31, 2019 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 4,637 $ — $ — $ 4,637 As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 5,358 $ — $ — $ 5,358

Note 4 - Inventories

Note 4 - Inventories	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	( 4 ) Inventories Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consist of the following (in thousands): December 31, 2019 2018 Raw materials $ — $ 79 Work in process — 39 Finished goods 4 23 Total $ 4 $ 141 Write downs for excess or expired inventory are based on management’s estimates of forecasted usage of inventories and are included in cost of goods sold. A significant change in the timing or level of demand for certain products as compared to forecasted amounts may $36,000, $12,000 $33,000 December 31, 2019, 2018 2017,

Note 5 - Property and Equipment

Note 5 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	( 5 ) Property and Equipment, Net Property and equipment, net consist of the following (in thousands): December 31, 2019 2018 Computer equipment and software $ 132 $ 119 Laboratory and manufacturing equipment 550 481 Furniture and fixtures 55 55 Leasehold improvements 332 332 Construction in progress 69 3 Property and equipment, gross 1,138 990 Less accumulated depreciation (957 ) (845 ) Property and equipment, net $ 181 $ 145 Depreciation expense totaled approximately $111,000, $88,000 $78,000 December 31, 2019, 2018 2017,

Note 6 - Lease

Note 6 - Lease	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	( 6 ) Lease The Company adopted the new lease standard on January 1, 2019 not The Company determines if an arrangement is a lease at inception by assessing whether it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company’s operating lease is primarily related to a property lease for its laboratory and corporate offices. BioCardia’s lease agreement does not ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company’s lease does not not no not The components of lease expense for the year ended December 31, 2019 December 31, 2019 Straight-line rent expense recognized for operating lease $ 601 Variable rent expense recognized for operating lease 264 Total rent expense $ 865 Weighted average remaining lease term (in years) 2.0 Weighted average discount rate 12.05 % Supplemental cash flow information related to the operating lease was as follows (in thousands): December 31, 2019 Cash paid for amounts included in the measurement of lease liabilities $ 612 Cash lease expense (imputed interest expense component of net income) $ 161 Future minimum lease payments under the operating lease as of December 31, 2019 For the years ended December 31, 2019 2020 $ 630 2021 649 Total undiscounted lease payments 1,279 Less imputed interest 137 Total operating lease liabilities $ 1,142 Prior to the Company’s adoption of the new lease standard, future minimum lease payments as of December 31, 2018, For the years ended December 31, 2018 2019 $ 612 2020 630 2021 649 Total undiscounted lease payments $ 1,891 Prior to the Company’s adoption of the new lease standard, rent expense was recognized on a straight-line basis over the life of the lease. Rental expense was approximately $601,000 December 31, 2018 2017.

Note 7 - Collaborative Agreemen

Note 7 - Collaborative Agreements	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	( 7 ) Collaborative Agreements The Company has entered into various collaborations related to clinical development. These agreements allow partners to utilize the Company’s enabling biotherapeutic delivery systems, including training and support during clinical and pre-clinical delivery of biotherapeutics. Under the terms of these agreements, the Company typically receives a use fee and payments for the systems and services provided. The Company gains access to certain data generated by its partners for use in its own product development efforts and also receives nonexclusive patent rights to any partner-discovered BioCardia technology improvement inventions. Revenue from collaborative agreements is recognized in the Consolidated Statements of Operations in the line “Collaboration agreement revenue”.

Note 8 - Accrued Expenses and O

Note 8 - Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Accrued Liabilities and Other Current Liabilities Disclosure [Text Block]	( 8 ) Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): December 31, 2019 2018 Accrued expenses $ 10 $ 127 Accrued salaries and employee benefits 652 368 Accrued director compensation 648 277 Accrued clinical trial costs 519 276 Grant liability 630 645 Customer deposits 102 112 Total $ 2,561 $ 1,805

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	( 9 ) Stockholders’ Equity Public Offering on Form S- 1 April 2019, 1 1 August 2, 2019, 1, 1,666,667 one $0.001 one $6.00 $6.30 five 11,958 $6.60 45 250,000 250,000 August 6, 2019. $8.84 September 4, 2019, 75,000 250,000 $420,000, $32,000. Up List to Nasdaq August 2, 2019 Convertible Note Financing July 5, 2019, $625,000 14.0% six January 5, 2020. 50% $52,000. $521,000. December 31, 2019 $112,000 $104,000 Upon the closing of the Company’s public offering of units on August 6, 2019 $633,000, 210,887 one one $3.00 one $8.00 Reverse Stock Split June 6, 2019 1 9 Sales of Unregistered Common Stock and Warrants December 24, 2018, 592,592 $6.75 one 296,296 $3.8 $200,000 six December 31, 2019 no $6.75 December 24, 2023. Warrants Number of Common Stock Warrants Weighted Average Exercise Price Balance, December 31, 2018 296,296 $ 6.75 Warrants for common stock sold 2,139,512 $ 6.30 Warrants for common stock exercised - Balance, December 31, 2019 2,435,808 $ 6.36

Note 10 - Share-based Compensat

Note 10 - Share-based Compensation	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	( 10 ) Share-Based Compensation BioCardia Lifesciences adopted, and the BioCardia Lifesciences shareholders approved, the 2002 2002 “2002 2002 not not 2002 2016, 2016 “2016 2016 2016 2002 2016 four ten no 2016 2016 2016 first 4% 268,997 June 6, 2019); may no December 31, 2019, 461,605 2016 The Company recognizes in the consolidated statements of operations the grant-date fair value of stock options and other equity-based compensation. Share-based compensation expense for the years ended December 31, 2019, 2018 2017 Years ended December 31, 2019 2018 2017 Cost of goods sold $ 191 $ 143 $ 140 Research and development 1,115 953 678 Selling, general and administrative 1,416 1,678 1,889 Share-based compensation expense $ 2,722 $ 2,774 $ 2,707 The following table summarizes activity under the Company’s stock option plans, including the 2002 2016 Options outstanding Number of shares Weighted average exercise price Weighted average remaining contractual term (years) Aggregate intrisinsic value Balance, December 31, 2018 608,547 $ 25.20 7.8 Stock options granted 254,785 5.28 Stock options exercised — — Stock options canceled (41,868 ) 26.86 Balance, December 31, 2019 821,464 $ 18.99 7.6 $ - Exercisable and vested, December 31, 2019 428,793 $ 23.62 6.6 $ - The aggregate intrinsic value represents the difference between the total pre-tax value (i.e., the difference between the Company’s stock price and the exercise price) of stock options outstanding as of December 31, 2019, $3.68 The total intrinsic value of options exercised during the years ended December 31, 2019, 2018 2017 $3,000 $400,000, December 31, 2019, 2018 2017 $3.87, $15.48 $52.20 Employee, Director and Non-employee Share-Based Compensation During the years ended December 31, 2019 2018, 254,785 188,716 Years ended December 31, 2019 2018 2017 Risk-free interest rate 1.40 - 2.14% 2.66 - 2.89% 1.76 - 2.25% Volatility 74 - 94% 81 - 83% 81 - 89% Dividend yield None None None Expected term (in years) 6.25 - 10.0 6.25 5.00 - 6.25 Unrecognized share-based compensation for employees, non-employee directors and non-employee options granted through December 31, 2019 $3.4 2.1 Share-Based Compensation (RSUs) During the year ended December 31, 2019, 34,713 The following summarizes the activity of non-vested RSUs: Weighted average grant date Number of fair value shares per share Balance, December 31, 2018 29,698 $ 25.56 RSUs granted 34,713 4.75 RSUs vested (27,430 ) 19.46 RSUs forfeited - — Balance, December 31, 2019 36,981 $ 10.56 RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The related compensation expense, which is based on the grant date fair value of the Company’s common stock multiplied by the number of units granted, is recognized ratably over the period during which the vesting restrictions lapse. Unrecognized share-based compensation for RSUs granted through December 31, 2019 $171,000 0.1 Nonemployee Share-Based Compensation During the year ended December 31, 2019 No. 2018 07, 718 2018 07 718, No December 31, 2018 2017, zero 5,139 $176,000 $768,000 December 31, 2018 2017 December 31, 2018 2017 Years ended December 31, 2018 2017 Risk-free interest rate 2.80 - 2.95% 2.25 - 2.40% Volatility 78 - 85% 81 - 87% Dividend yield None None Expected term (in years) 7.6 - 8.8 8.6 - 9.8

Note 11 - Concentrations

Note 11 - Concentrations	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	( 11 ) Concentrations Most of the Company’s customers are located in the United States. Two 43% 25% 2019. One 29% 2018 no 10% 2017. One 15% December 31, 2019. One 23% December 31, 2018.

Note 12 - Net Loss Per Share

Note 12 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	( 12 ) Net Loss per Share The following table sets forth the computation of the basic and diluted net loss per share for the years ended December 31, 2019, 2018 2017 Years ended December 31, 2019 2018 2017 Numerator: Net loss $ (14,709 ) $ (13,987 ) $ (12,308 ) Denominator: Weighted average shares used to compute net loss per share, basic and diluted 5,644,328 4,264,178 4,240,060 Net loss per share, basic and diluted $ (2.61 ) $ (3.28 ) $ (2.90 ) The following weighted-average outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: Years ended December 31, 2019 2018 2017 Stock options to purchase common stock 821,464 608,547 468,122 Unvested restricted stock units 36,981 29,698 10,888 Common stock warrants 2,435,808 296,296 - Total 3,294,253 934,541 479,010

Note 13 - Income Taxes

Note 13 - Income Taxes	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	( 13 ) Income Taxes The Company’s provision for income taxes for the years ended December 31, 2019, 2018 2017 $0 The provision for income taxes differs from the amount which would result by applying the federal statutory income tax rate to pre-tax loss for the years ended December 31, 2019, 2018 2017. Years ended December 31, 2019 2018 2017 Tax at federal statutory rate $ (3,089 ) $ (2,937 ) $ (4,185 ) State, net of federal benefit (414 ) (455 ) (1,238 ) Research and development credit (225 ) (236 ) (135 ) Stock-based compensation 446 440 344 Change in Federal Tax Rate - - 8,172 Other 5 22 7 Change in valuation allowance 3,277 3,166 (2,965 ) Total provision for income taxes $ — $ - $ - Deferred income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss and tax credit carryforwards, net of any adjustment for unrecognized tax benefits. The components of the net deferred income tax assets as of December 31, 2019 2018 Years ended December 31, 2019 2018 Accrued compensation $ 148 $ 84 Inventory adjustments 297 276 Depreciation and amortization 98 113 Stock-based compensation 744 648 Net operating loss and tax credit carryforwards 23,809 20,698 Other 11 12 Gross Deferred Tax Asset 25,107 21,831 Valuation Allowance (25,107 ) (21,831 ) Net deferred tax asset $ - $ - The Company has approximately $80.5 $58.6 December 31, 2019. 2022 2028 2019 2018 no Generally, utilization of the net operating loss carryforwards and credits may 382, 383, 1986, may not 382 At December 31, 2019, $2.4 $1.8 2028. no The Company does not not not December 31, 2019 2018. December 31, 2019 $3.2 December 31, 2018 $3.2 No The aggregate changes in the balance of gross unrecognized tax benefits were as follows (in thousands): Years ended December 31, 2019 2018 Balance, beginning of year $ 891 $ 725 Additions based on tax positions related to the current year 155 166 Balance, end of year $ 1,046 $ 891 Recognition of approximately $753,000 $636,000 December 31, 2019 2018 2018 2019 The Company is subject to U.S. federal, California, Colorado, Florida and Minnesota income taxes. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company was incorporated in 2002

Note 14 - Contingencies

Note 14 - Contingencies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Contingencies Disclosure [Text Block]	( 14 ) Contingencies and Uncertainties Contingencies may not Uncertainties December 31, 2019, 19 19 not December 31, 2019. In March 2020, 19, may third may may 19 may may Additionally, while the potential economic impact brought by, and the duration of, a coronavirus pandemic is difficult to assess or predict, the impact of the coronavirus on the global financial markets may not third

Note 15 - Grant Funding

Note 15 - Grant Funding	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Grant Funding [Text Block]	( 15 ) Grant Funding In June 2016, 1998 not $750,000 three June 2020. As of December 31, 2019, $750,000 $120,000 December 31, 2019. $630,000 December 31, 2019.

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	( 16 ) Related Party Transactions OPKO BioCardia, Inc. (the “Company”) and OPKO Health, Inc. (“OPKO”) previously entered into a consulting agreement dated August 19, 2016, 5% Pursuant to the terms of the Consulting Agreement, OPKO was to provide advisory services to the Company in support of strategic transactions, financings and other matters as agreed between the parties from time to time. Also, in August 2016, ten 46,553 4 $16.20 4 one Effective August 29, 2019, no ten August 2019. $225,000 $167,000 December 31, 2019. $142,000 $480,000 December 31, 2018 2017, Convertible Note Financing On July 5, 2019, $625,000 9 Sales of Unregistered Common Stock and Warrants On December 24, 2018, 592,592 $6.75 one 296,296 $3.8 $200,000 9

Note 17 - Employee Benefit Plan

Note 17 - Employee Benefit Plans	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Retirement Benefits [Text Block]	( 17 ) Employee Benefit Plans The Company’s U.S. employees are eligible to participate in a retirement and savings plan that qualifies under Section 401 may 75% not $25,000 $26,000 December 31, 2019 2018, not December 31, 2017.

Note 18 - Subsequent Events

Note 18 - Subsequent Events	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	( 18 ) Subsequent Events On November 26, 2019, 2019 one 515,036 $10.05 $97.21 2002 2016 January 29, 2020 $5.32 not In March 2020, 19, not

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	(a) Basis of Presentation and Consolidation These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All material intercompany accounts and transactions have been eliminated during the consolidation process. Certain changes in the prior period consolidated balance sheet have been made to conform to the current period presentation. Specifically, accounts payable was decreased by $277,000 December 31, 2018 December 31, 2018, 2017, 2016 $39,000 2019 no
Going Concern and Liquidity [Policy Text Block]	(b) Liquidity - Going Concern The Company has incurred net losses and negative cash flows from operations since its inception and had an accumulated deficit of $101.1 December 31, 2019. $5.6 December 31, 2019 not second 2020. one not The Company’s ability to continue as a going concern and to continue further development of its therapeutic candidates beyond the second 2020, not not may may
Use of Estimates, Policy [Policy Text Block]	(c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires Company management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property and equipment, right-of-use assets and related liabilities, allowances for doubtful accounts and sales returns; inventory valuation, derivative instruments, clinical accruals, and share-based compensation.
Cash and Cash Equivalents, Policy [Policy Text Block]	(d) Cash Equivalents The Company classifies all highly liquid investments with an original maturity date of 90
Concentration Risk, Credit Risk, Policy [Policy Text Block]	(e) Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At December 31, 2019, one not not
Accounts Receivable [Policy Text Block]	(f) Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and do not not $2,000 $9,000 December 31, 2019 2018,
Inventory, Policy [Policy Text Block]	(g) Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the average-cost method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company analyzes its inventory levels quarterly and writes down inventory that has become obsolete or has a cost basis in excess of its expected net realizable value or inventory quantities in excess of expected requirements. Excess requirements are determined based on comparison of existing inventories to forecasted sales, with consideration given to inventory shelf life. Expired inventory is disposed of and the related costs are recognized in cost of goods sold.
Property, Plant and Equipment, Policy [Policy Text Block]	(h) Property and Equipment, Net Property and equipment, net, are carried at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets, as described in the table below. Maintenance and repairs are expensed as incurred. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is reflected in the accompanying consolidated statements of operations. Asset Estimated useful lives (in years) Computer equipment and software 3 Laboratory and manufacturing equipment 3 Furniture and fixtures 3 Leasehold improvements 5 years or lease term, if shorter
Lessee, Leases [Policy Text Block]	(i) Right-of-Use Assets Operating lease right-of-use asset and liabilities 12 The Company’s lease liabilities are recognized at the applicable lease commencement date based on the present value of the lease payments required to be paid over the lease term. Variable lease payments are expensed as incurred and are not The Company's ROU assets are also recognized at the applicable lease commencement date. The ROU asset equals the carrying amount of the related lease liability, adjusted for any lease payments made prior to lease commencement and lease incentives provided by the lessor, if any. The Company reduces a right-of-use (ROU) asset, and the periodic reduction is the difference between the straight-line total lease cost for the period (including reduction of initial direct costs) and the periodic accretion of the lease liability using the effective interest method. The Company’s lease terms may The Company’s lease contracts often include lease and non-lease components. The Company has elected the practical expedient offered by the standard to not The Company has elected not twelve
Property, Plant and Equipment, Impairment [Policy Text Block]	(j) Long-lived Assets Impairment assessment of long - lived assets may not December 31, 2019, no
Clinical Trial Accruals, Policy [Policy Text Block]	( k ) Clinical Trial Accruals As part of the process of preparing its consolidated financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiation and may not not may may
Derivatives, Policy [Policy Text Block]	( l ) Derivatives The Company accounts for its derivative instruments as either assets or liabilities on the consolidated balance sheet and measures them at fair value. Derivatives are adjusted to fair value through other (expense) income, net in the consolidated statements of operations.
Deferred Rent [Policy Text Block]	( m ) Deferred Rent Prior to the adoption of ASU No. 2018 11, 842
Revenue [Policy Text Block]	( n ) Revenue Recognition Net product revenue Collaboration agreement revenue In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may not The Company applies judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, if over time, concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in the Company’s estimated measure of progress are accounted for prospectively as a change in accounting estimate. The Company recognizes collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. The Company will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in the Company’s balance sheets. If the related performance obligation is expected to be satisfied within the next twelve may not one December 31, 2019, $691,000 $191,000 $500,000 July 2021. Multiple contracts with the same customer - two one one Contract costs - one not Contract modifications - one not not not
Shipping and Handling, Policy [Policy Text Block]	( o ) Shipping Costs Costs incurred for the shipping of products to customers totaled approximately $6,000, $6,000 $5,000 December 31, 2019, 2018 2017,
Standard Product Warranty, Policy [Policy Text Block]	( p ) Product Warranties The Company provides a standard warranty of serviceability on all its products for the duration of the product’s shelf life, which is two not December 31, 2019 2018.
Research and Development Expense, Policy [Policy Text Block]	( q ) Research and Development The Company’s research and development costs are expensed as incurred. Research and development expense include the costs of basic research activities as well as other research, engineering, and technical effort required to develop new products or services or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and support costs for collaborative partnering programs wherein the Company provides biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. The Company’s research and development costs consist primarily of: • Salaries, benefits and other personnel-related expenses, including share-based compensation • Fees paid for services provided by clinical research organizations, research institutions, consultants and other outside service providers • Costs to acquire and manufacture materials used in research and development activities and clinical trials • Laboratory consumables and supplies • Facility-related expenses allocated to research and development activities • Fees to collaborators to license technology • Depreciation expense for equipment used for research and development and clinical purposes.
Cost of Goods and Service [Policy Text Block]	(r ) Cost of Goods Sold
Compensation Related Costs, Policy [Policy Text Block]	(s ) Share-Based Compensation The Company measures and recognizes share-based compensation expense for equity awards to employees, directors and consultants based on fair value at the grant date. The Company uses the Black-Scholes option pricing model to calculate fair value of its stock option grants. The compensation cost for restricted stock awards is based on the closing price of the Company’s common stock on the date of grant. Share-based compensation expense recognized in the consolidated statements of operations is based on the period the services are performed and recognized as compensation expense on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur. Measurement of nonemployee awards - The measurement of equity-classified nonemployee awards is fixed at the grant date, and the Company may 505 50 The Black-Scholes option pricing model (BSM) requires the input of subjective assumptions, including the risk-free interest rate, the expected volatility in the value of the Company’s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, the share-based compensation expense could be materially different in the future. These assumptions are estimated as follows: Risk-free Interest Rate The risk-free interest rate assumption is based on the zero Expected Volatility The Company has limited historical data of its own to utilize in determining expected volatility. As such the Company based the volatility assumption on a combined weighted average of the Company’s own historical data and that of a selected peer group. The peer group was developed based on companies in the biotechnology and medical device industries whose shares are publicly-traded. Expected Term The expected term represents the period of time that options are expected to be outstanding. As the Company does not
Income Tax, Policy [Policy Text Block]	(t ) Income Taxes The Company accounts for income taxes based on the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets, liabilities, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not not In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, forecasts of future taxable income, and ongoing tax planning. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not The Company recognizes and measures benefits for uncertain tax positions using a two first not not second 50% No
Fair Value of Financial Instruments, Policy [Policy Text Block]	(u ) Fair Value of Financial Instruments The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the consolidated financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Where observable prices or inputs are not The Company’s financial assets and liabilities consist principally of cash and cash equivalents, accounts receivable, and accounts payable. The fair value of the Company’s cash equivalents is determined based on quoted prices in active markets for identical assets. The recorded values of the Company’s accounts receivable and accounts payable approximate their current fair values due to the relatively short-term nature of these accounts.
Earnings Per Share, Policy [Policy Text Block]	(v ) Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Common stock equivalents are comprised of restricted stock units, warrants to purchase common stock and options outstanding under the stock option plans. For all periods presented, there is no
New Accounting Pronouncements, Policy [Policy Text Block]	(w ) Recently Adopted Accounting Pronouncements In February 2016, No. 2016 02, Leases (Topic 842 2016 02” July 2018, No. 2018 11, 842 No. 2018 11. No. 2018 11, 2016 02, The Company adopted the new standard using the cumulative-effect method on January 1, 2019. March 2019. The FASB made available several practical expedients in adopting the amended lease accounting guidance. The Company elected the package of practical expedients permitted under the transition guidance, which among other things, allowed registrants to carry forward historical lease classification, its assessment on whether a contract is or contains a lease, and its initial direct costs for any leases that exist prior to adoption of the new standard. BioCardia also elected to keep leases with an initial term of 12 The most significant impact was the recognition of ROU assets and related lease liabilities for operating leases on the condensed consolidated balance sheet. The Company recognized ROU assets and related lease liabilities of $1,505,000 $1,593,000 January 1, 2019. not 6 In June 2018, No. 2018 07, 718 2018 07 2018 07 718, No 2018 07 505 50, 2018 07 January 1, 2019 not not In May 2014, No. 2014 09, 605, 606, 2015 2016, 606 January 1, 2018 In May 2017, No. 2017 09 718 2017 09 718. 2016 01 January 1, 2018, not ( x ) Recent Accounting Pronouncements In August 2018, No. 2018 13, 820 2018 13 820. 3 2018 13 December 15, 2019, not In November 2018, No. 2018 18, 808 808 606 2018 18” 2018 18 606 606 2018 18 December 15, 2019, 2018 18 606. not In December 2019, 2019 12 740 December 15, 2020, In June 2016, No. 2016 13, 326 December 15, 2022, not Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did not not

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment, Useful Life [Table Text Block]	Asset Estimated useful lives (in years) Computer equipment and software 3 Laboratory and manufacturing equipment 3 Furniture and fixtures 3 Leasehold improvements 5 years or lease term, if shorter

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	As of December 31, 2019 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 4,637 $ — $ — $ 4,637 As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 5,358 $ — $ — $ 5,358

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2019 2018 Raw materials $ — $ 79 Work in process — 39 Finished goods 4 23 Total $ 4 $ 141

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2019 2018 Computer equipment and software $ 132 $ 119 Laboratory and manufacturing equipment 550 481 Furniture and fixtures 55 55 Leasehold improvements 332 332 Construction in progress 69 3 Property and equipment, gross 1,138 990 Less accumulated depreciation (957 ) (845 ) Property and equipment, net $ 181 $ 145

Note 6 - Lease (Tables)

Note 6 - Lease (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Lease, Cost [Table Text Block]	December 31, 2019 Straight-line rent expense recognized for operating lease $ 601 Variable rent expense recognized for operating lease 264 Total rent expense $ 865 Weighted average remaining lease term (in years) 2.0 Weighted average discount rate 12.05 %
Schedule of Operating Leases Cash Flow Information [Table Text Block]	December 31, 2019 Cash paid for amounts included in the measurement of lease liabilities $ 612 Cash lease expense (imputed interest expense component of net income) $ 161
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	For the years ended December 31, 2019 2020 $ 630 2021 649 Total undiscounted lease payments 1,279 Less imputed interest 137 Total operating lease liabilities $ 1,142
Lessee, Operating Lease, Disclosure [Table Text Block]	For the years ended December 31, 2018 2019 $ 612 2020 630 2021 649 Total undiscounted lease payments $ 1,891

Note 8 - Accrued Expenses and_2

Note 8 - Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block]	December 31, 2019 2018 Accrued expenses $ 10 $ 127 Accrued salaries and employee benefits 652 368 Accrued director compensation 648 277 Accrued clinical trial costs 519 276 Grant liability 630 645 Customer deposits 102 112 Total $ 2,561 $ 1,805

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Common Stock Warrants Weighted Average Exercise Price Balance, December 31, 2018 296,296 $ 6.75 Warrants for common stock sold 2,139,512 $ 6.30 Warrants for common stock exercised - Balance, December 31, 2019 2,435,808 $ 6.36

Note 10 - Share-based Compens_2

Note 10 - Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Share-based Compensation, Expense [Table Text Block]	Years ended December 31, 2019 2018 2017 Cost of goods sold $ 191 $ 143 $ 140 Research and development 1,115 953 678 Selling, general and administrative 1,416 1,678 1,889 Share-based compensation expense $ 2,722 $ 2,774 $ 2,707
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Options outstanding Number of shares Weighted average exercise price Weighted average remaining contractual term (years) Aggregate intrisinsic value Balance, December 31, 2018 608,547 $ 25.20 7.8 Stock options granted 254,785 5.28 Stock options exercised — — Stock options canceled (41,868 ) 26.86 Balance, December 31, 2019 821,464 $ 18.99 7.6 $ - Exercisable and vested, December 31, 2019 428,793 $ 23.62 6.6 $ -
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Weighted average grant date Number of fair value shares per share Balance, December 31, 2018 29,698 $ 25.56 RSUs granted 34,713 4.75 RSUs vested (27,430 ) 19.46 RSUs forfeited - — Balance, December 31, 2019 36,981 $ 10.56
Non-employee Stock Options [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Years ended December 31, 2018 2017 Risk-free interest rate 2.80 - 2.95% 2.25 - 2.40% Volatility 78 - 85% 81 - 87% Dividend yield None None Expected term (in years) 7.6 - 8.8 8.6 - 9.8
Share-based Payment Arrangement, Option [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Years ended December 31, 2019 2018 2017 Risk-free interest rate 1.40 - 2.14% 2.66 - 2.89% 1.76 - 2.25% Volatility 74 - 94% 81 - 83% 81 - 89% Dividend yield None None None Expected term (in years) 6.25 - 10.0 6.25 5.00 - 6.25

Note 12 - Net Loss Per Share (T

Note 12 - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Years ended December 31, 2019 2018 2017 Numerator: Net loss $ (14,709 ) $ (13,987 ) $ (12,308 ) Denominator: Weighted average shares used to compute net loss per share, basic and diluted 5,644,328 4,264,178 4,240,060 Net loss per share, basic and diluted $ (2.61 ) $ (3.28 ) $ (2.90 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Years ended December 31, 2019 2018 2017 Stock options to purchase common stock 821,464 608,547 468,122 Unvested restricted stock units 36,981 29,698 10,888 Common stock warrants 2,435,808 296,296 - Total 3,294,253 934,541 479,010

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Years ended December 31, 2019 2018 2017 Tax at federal statutory rate $ (3,089 ) $ (2,937 ) $ (4,185 ) State, net of federal benefit (414 ) (455 ) (1,238 ) Research and development credit (225 ) (236 ) (135 ) Stock-based compensation 446 440 344 Change in Federal Tax Rate - - 8,172 Other 5 22 7 Change in valuation allowance 3,277 3,166 (2,965 ) Total provision for income taxes $ — $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Years ended December 31, 2019 2018 Accrued compensation $ 148 $ 84 Inventory adjustments 297 276 Depreciation and amortization 98 113 Stock-based compensation 744 648 Net operating loss and tax credit carryforwards 23,809 20,698 Other 11 12 Gross Deferred Tax Asset 25,107 21,831 Valuation Allowance (25,107 ) (21,831 ) Net deferred tax asset $ - $ -
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Years ended December 31, 2019 2018 Balance, beginning of year $ 891 $ 725 Additions based on tax positions related to the current year 155 166 Balance, end of year $ 1,046 $ 891

Note 2 - Significant Accounti_3

Note 2 - Significant Accounting Policies 1 (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2019
Accounts Payable, Current, Total	$ 914,000	$ 743,000
Accrued Liabilities and Other Liabilities, Current	2,561,000	1,805,000
Adjustments to Equity to Reflect the Impact of Reverse Stock Split		39,000	$ 39,000	$ 39,000
Retained Earnings (Accumulated Deficit), Ending Balance	(101,070,000)	(86,361,000)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	5,585,000	5,358,000	12,689,000	$ 21,352,000
Accounts Receivable, Allowance for Credit Loss, Current	2,000	9,000
Impairment of Long-Lived Assets Held-for-use	0
Cost of Goods and Services Sold, Total	$ 358,000	517,000	690,000
Standard Product Warranty, Term (Year)	2 years
Standard Product Warranty Accrual, Ending Balance	$ 0	0
Income Tax Examination, Penalties and Interest Accrued, Total	0
Operating Lease, Right-of-Use Asset	1,065,000
Operating Lease, Liability, Total	1,142,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset					$ 1,505,000
Operating Lease, Liability, Total					$ 1,593,000
Shipping and Handling [Member]
Cost of Goods and Services Sold, Total	$ 6,000	6,000	$ 5,000
Revision of Prior Period, Adjustment [Member]
Accounts Payable, Current, Total		(277,000)
Accrued Liabilities and Other Liabilities, Current		$ 277,000

Note 2 - Significant Accounti_4

Note 2 - Significant Accounting Policies 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01	Dec. 31, 2019USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month)	1 year 210 days
Revenue, Remaining Performance Obligation, Amount	$ 691,000
Service [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month)	1 year 210 days
Revenue, Remaining Performance Obligation, Amount	$ 191,000
License [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month)	1 year 210 days
Revenue, Remaining Performance Obligation, Amount	$ 500,000

Note 2 - Significant Accounti_5

Note 2 - Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2019
Computer Equipment and Software [Member]
Estimated useful lives (Year)	3 years
Laboratory and Manufacturing Equipment [Member]
Estimated useful lives (Year)	3 years
Furniture and Fixtures [Member]
Estimated useful lives (Year)	3 years
Leasehold Improvements [Member]
Estimated useful lives	5 years or lease term, if shorter

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Money market funds	$ 4,637	$ 5,358
Fair Value, Inputs, Level 1 [Member]
Money market funds	4,637	5,358
Fair Value, Inputs, Level 2 [Member]
Money market funds
Fair Value, Inputs, Level 3 [Member]
Money market funds

Note 4 - Inventories (Details T

Note 4 - Inventories (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Inventory Write-down	$ 1,000
Cost of Goods Sold [Member]
Inventory Write-down	$ 36,000	$ 12,000	$ 33,000

Note 4 - Inventories - Summary

Note 4 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Raw materials		$ 79
Work in process		39
Finished goods	4	23
Total	$ 4	$ 141

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Depreciation, Total	$ 111,000	$ 88,000	$ 78,000

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, gross	$ 1,138	$ 990
Less accumulated depreciation	(957)	(845)
Property and equipment, net	181	145
Computer Equipment and Software [Member]
Property and equipment, gross	132	119
Laboratory and Manufacturing Equipment [Member]
Property and equipment, gross	550	481
Furniture and Fixtures [Member]
Property and equipment, gross	55	55
Leasehold Improvements [Member]
Property and equipment, gross	332	332
Construction in Progress [Member]
Property and equipment, gross	$ 69	$ 3

Note 6 - Lease (Details Textual

Note 6 - Lease (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating Lease, Expense	$ 601,000	$ 601,000	$ 601,000

Note 6 - Lease - Impact of New

Note 6 - Lease - Impact of New Lease Standard (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Straight-line rent expense recognized for operating lease	$ 601,000	$ 601,000	$ 601,000
Variable rent expense recognized for operating lease	264,000
Total rent expense	$ 865,000
Weighted average remaining lease term (in years) (Year)	2 years
Weighted average discount rate	12.05%

Note 6 -Lease - Supplement Cash

Note 6 -Lease - Supplement Cash Flow Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Cash paid for amounts included in the measurement of lease liabilities	$ 612
Cash lease expense (imputed interest expense component of net income)	$ 161

Note 6 - Lease - Future Minimum

Note 6 - Lease - Future Minimum Lease Payments Under Operating Lease (Details) $ in Thousands	Dec. 31, 2019USD ($)
2020	$ 630
2021	649
Total undiscounted lease payments	1,279
Less imputed interest	137
Total operating lease liabilities	$ 1,142

Note 6 -Lease - Future Minimum

Note 6 -Lease - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2019USD ($)
2019	$ 612
2020	630
2021	649
Total undiscounted lease payments	$ 1,891

Note 8 - Accrued Expenses and_3

Note 8 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued expenses	$ 10	$ 127
Accrued salaries and employee benefits	652	368
Accrued director compensation	648	277
Accrued clinical trial costs	519	276
Grant liability	630	645
Customer deposits	102	112
Total	$ 2,561	$ 1,805

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual)	Sep. 04, 2019USD ($)shares	Aug. 06, 2019USD ($)$ / sharesshares	Aug. 06, 2019USD ($)$ / sharesshares	Aug. 02, 2019$ / sharesshares	Jul. 05, 2019USD ($)shares	Jun. 06, 2019	Dec. 24, 2018USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)	Aug. 05, 2019$ / shares
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares									$ 0.001	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 6.75		$ 6.36	$ 6.75
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							296,296
Stock Issued During Period, Shares, New Issues (in shares)							592,592
Class of Warrant or Right, Issued During Period (in shares)									2,139,512
Common Stock, Shares, Issued, Total (in shares)							592,592		6,825,183	4,845,697
Sale of Stock, Price Per Share (in dollars per share) | $ / shares							$ 6.75
Proceeds from Issuance of Common Stock and Warrants | $							$ 3,800,000		$ 10,452,000	$ 4,000,000
Payments of Stock Issuance Costs | $							$ 200,000		$ 1,259,000	$ 200,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio						9
Conversion of Convertible Notes to Units [Member]
Debt Conversion, Original Debt, Amount | $			$ 633,000		$ 52,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)			210,887		521,000
Interest Expense, Debt, Total | $								$ 112,000
Amortization of Debt Discount (Premium) | $								$ 104,000
Convertible Promissory Note [Member]
Proceeds from Convertible Debt | $					$ 625,000
Debt Instrument, Interest Rate, Stated Percentage					14.00%
Debt Conversion, Original Debt, Discount of Securities Offered					50.00%
Underwriters [Member]
Proceeds from Issuance or Sale of Equity, Total | $	$ 420,000
Stock Issued During Period, Shares, New Issues (in shares)	75,000
Class of Warrant or Right, Issued During Period (in shares)	250,000
Underwriting Discounts and Commissions | $	$ 32,000
Warrants Issued to Underwriters [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 6.60
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				11,958
Public Offering [Member]
Number of Units Offered to Sale (in shares)				1,666,667
Number of Common Stock in Each Unit (in shares)				1
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 0.001
Number of Common Stock Called by Each Unit (in shares)				1
Unit Offering Price (in dollars per share) | $ / shares				$ 6
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 6.30
Warrants and Rights Outstanding, Term (Year)				5 years
Underwriters, Additional Common Shares Authorized to Purchase (in shares)				250,000
Underwriters, Additional Warrants Authorized to Purchase (in shares)				250,000
Proceeds from Issuance or Sale of Equity, Total | $		$ 8,840,000
Private Placement Unit [Member]
Number of Common Stock in Each Unit (in shares)		1	1
Number of Common Stock Called by Each Unit (in shares)		1	1
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 3	$ 3									$ 8

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Warrants (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Balance, December 31, 2018 (in shares) | shares	296,296
Balance, December 31, 2018 (in dollars per share) | $ / shares	$ 6.75
Warrants for common stock sold (in shares) | shares	2,139,512
Warrants for common stock sold (in dollars per share) | $ / shares	$ 6.30
Balance, December 31, 2019 (in shares) | shares	2,435,808
Balance, December 31, 2019 (in dollars per share) | $ / shares	$ 6.36

Note 10 - Share-based Compens_3

Note 10 - Share-based Compensation (Details Textual) - USD ($)	Nov. 26, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share Price (in dollars per share)		$ 3.68
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 0	$ 3,000	$ 400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 3.87	$ 15.48	$ 52.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	515,036	254,785
Share-based Payment Arrangement, Noncash Expense, Total		$ 2,722,000	$ 2,774,000	$ 2,707,000
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		254,785	188,716
Non-employee Directors and Employees [Member]
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount		$ 3,400,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years 36 days
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			0	5,139
Non-employees [Member]
Share-based Payment Arrangement, Noncash Expense, Total			$ 176,000	$ 768,000
The 2016 Plan [Member]
Annual Increase, Number of Common Shares (in shares)		268,997
Annual Increase, Percentage of Common Shares Outstanding		4.00%
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
Share-based Payment Arrangement, Option [Member] | The 2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		461,605
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount		$ 171,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		36 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		34,713
Restricted Stock Units (RSUs) [Member] | Non-employee Directors and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		34,713

Note 10 - Share-based Compens_4

Note 10 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based compensation expense	$ 2,722	$ 2,774	$ 2,707
Cost of Goods Sold [Member]
Share-based compensation expense	191	143	140
Research and Development Expense [Member]
Share-based compensation expense	1,115	953	678
Selling, General and Administrative Expenses [Member]
Share-based compensation expense	$ 1,416	$ 1,678	$ 1,889

Note 10 - Share-based Compens_5

Note 10 - Share-based Compensation - Stock Option Activity (Details) - USD ($)	Nov. 26, 2019	Dec. 31, 2019	Dec. 31, 2018
Stock options outstanding, beginning of period (in shares)		608,547
Balance, weighted average exercise price, beginning of period (in dollars per share)		$ 25.20
Stock options outstanding, weighted average remaining contractual term (Year)		7 years 219 days	7 years 292 days
Stock options outstanding, aggregate intrinsic value
Stock options granted (in shares)	515,036	254,785
Stock options granted, weighted average exercise price (in dollars per share)		$ 5.28
Stock options exercised (in shares)
Stock options exercised, weighted average exercise price (in dollars per share)
Stock options canceled (in shares)		(41,868)
Stock options canceled, weighted average exercise price (in dollars per share)		$ 26.86
Stock options outstanding, end of period (in shares)		821,464	608,547
Balance, weighted average exercise price, end of period (in dollars per share)		$ 18.99	$ 25.20
Exercisable and vested (in shares)		428,793
Exercisable and vested, weighted average exercise price (in dollars per share)		$ 23.62
Exercisable and vested, weighted average remaining contractual term (Year)		6 years 219 days
Exercisable and vested, aggregate intrinsic value

Note 10 - Share-based Compens_6

Note 10 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) - Share-based Payment Arrangement, Option [Member]	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Dividend yield	0.00%	0.00%	0.00%
Expected term (Year)		6 years 91 days
Minimum [Member]
Risk-free interest rate	1.40%	2.66%	1.76%
Volatility	74.00%	81.00%	81.00%
Expected term (Year)	6 years 91 days		5 years
Maximum [Member]
Risk-free interest rate	2.14%	2.89%	2.25%
Volatility	94.00%	83.00%	89.00%
Expected term (Year)	10 years		6 years 91 days

Note 10 - Share-based Compens_7

Note 10 - Share-based Compensation - Summary of Non-vested RSUs (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Balance, shares (in shares) | shares	29,698
Balance, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 25.56
RSUs granted, shares (in shares) | shares	34,713
RSUs granted, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 4.75
RSUs vested, shares (in shares) | shares	(27,430)
RSUs vested, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 19.46
RSUs forfeited, shares (in shares) | shares
RSUs forfeited, weighted average grant date fair value per share (in dollars per share) | $ / shares
Balance, shares (in shares) | shares	36,981
Balance, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 10.56

Note 10 - Share-based Compens_8

Note 10 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) - Non-employee Stock Options [Member]	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Dividend yield	0.00%	0.00%
Minimum [Member]
Risk-free interest rate	2.80%	2.25%
Volatility	78.00%	81.00%
Expected term (Year)	7 years 219 days	8 years 219 days
Maximum [Member]
Risk-free interest rate	2.95%	2.40%
Volatility	85.00%	87.00%
Expected term (Year)	8 years 292 days	9 years 292 days

Note 11 - Concentrations (Detai

Note 11 - Concentrations (Details Textual) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue Benchmark [Member]
Concentration Risk, Percentage		29.00%
Number of Major Customers	2	1	0
Revenue Benchmark [Member] | Customer One [Member]
Concentration Risk, Percentage	43.00%
Revenue Benchmark [Member] | Customer Two [Member]
Concentration Risk, Percentage	25.00%
Accounts Receivable [Member]
Concentration Risk, Percentage	15.00%	23.00%
Number of Major Customers	1	1

Note 12 - Net Loss Per Share -

Note 12 - Net Loss Per Share - Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net loss	$ (14,709)	$ (13,987)	$ (12,308)
Weighted-average shares used in computing net loss per share, basic and diluted (in shares)	5,644,328	4,264,178	4,240,060
Net loss per share, basic and diluted (in dollars per share)	$ (2.61)	$ (3.28)	$ (2.90)

Note 12 - Net Loss Per Share _2

Note 12 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Antidilutive securities (in shares)	3,294,253	934,541	479,010
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	821,464	608,547	468,122
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)	36,981	29,698	10,888
Warrant [Member]
Antidilutive securities (in shares)	2,435,808	296,296

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Expense (Benefit), Total	$ 0	$ 0	$ 0
Deferred Tax Liabilities, Net, Total	0	0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	3,200,000	3,200,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	753,000	$ 636,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	80,500,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	2,400,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	58,600,000
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 1,800,000

Note 13 - Income Taxes - Effect

Note 13 - Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Tax at federal statutory rate	$ (3,089,000)	$ (2,937,000)	$ (4,185,000)
State, net of federal benefit	(414,000)	(455,000)	(1,238,000)
Research and development credit	(225,000)	(236,000)	(135,000)
Stock-based compensation	446,000	440,000	344,000
Change in Federal Tax Rate			8,172,000
Other	5,000	22,000	7,000
Change in valuation allowance	3,277,000	3,166,000	(2,965,000)
Total provision for income taxes	$ 0	$ 0	$ 0

Note 13 - Income Taxes - Compon

Note 13 - Income Taxes - Components of the Net Deferred Income Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued compensation	$ 148	$ 84
Inventory adjustments	297	276
Depreciation and amortization	98	113
Stock-based compensation	744	648
Net operating loss and tax credit carryforwards	23,809	20,698
Other	11	12
Gross Deferred Tax Asset	25,107	21,831
Valuation Allowance	(25,107)	(21,831)
Net deferred tax asset

Note 13 - Income Taxes - Aggreg

Note 13 - Income Taxes - Aggregate Changes in the Balance of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Balance, beginning of year	$ 891	$ 725
Additions based on tax positions related to the current year	155	166
Balance, end of year	$ 1,046	$ 891

Note 15 - Grant Funding (Detail

Note 15 - Grant Funding (Details Textual) - Grant Agreement [Member] - TEDCO [Member] - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2019
Grant Funding Available	$ 750,000
Grant Funding, Term of Grant (Year)	3 years
Proceeds from Grant Funding		$ 750,000
Research and Development Expense Reduction from Qualified Grant Funding		120,000
Deferred Revenue from Grants, Current		$ 630,000

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Details Textual) - USD ($)	Nov. 26, 2019	Jul. 05, 2019	Dec. 24, 2018	Aug. 31, 2016	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Aug. 19, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	515,036				254,785
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)					$ 18.99	$ 25.20
Share-based Payment Arrangement, Noncash Expense, Total					$ 2,722,000	$ 2,774,000	$ 2,707,000
Stock Issued During Period, Shares, New Issues (in shares)			592,592
Sale of Stock, Price Per Share (in dollars per share)			$ 6.75
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			0.5
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			296,296
Proceeds from Issuance of Common Stock and Warrants			$ 3,800,000		10,452,000	4,000,000
Payments of Stock Issuance Costs			$ 200,000		1,259,000	200,000
Convertible Promissory Note [Member]
Proceeds from Convertible Debt		$ 625,000
Chairman and Chief Executive Officer of OPKO [Member]
Related Party, Ownership Percentage								5.00%
OPKO [Member] | Consulting Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)				46,553
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)				4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)				$ 16.20
Consulting Agreement, Term (Year)				4 years
Consulting Agreement, Term, Length of Automatic Renewal Periods (Year)				1 year
OPKO [Member] | Chairman and Chief Executive Officer of OPKO [Member]
Share-based Payment Arrangement, Noncash Expense, Total					225,000	$ 142,000	$ 480,000
Share-based Payment Arrangement, Options Modifications					$ 167,000

Note 17 - Employee Benefit Pl_2

Note 17 - Employee Benefit Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	75.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 25,000	$ 26,000	$ 0

Note 18 - Subsequent Events (De

Note 18 - Subsequent Events (Details Textual) - $ / shares	Jan. 29, 2020	Nov. 26, 2019	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		515,036	254,785
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			$ 5.28
Subsequent Event [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)	$ 5.32
Minimum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 10.05
Maximum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 97.21